Phase 4 plaque Clinical Trials
8 recruitingPhase 4
What is a Phase 4 trial?
Phase 4 trials, also called post-marketing studies, are conducted after a treatment has been approved and is available to the public. They monitor long-term effectiveness and safety in a broader population.
Showing 1–8 of 8 trials
Recruiting
Phase 4
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
Plaque, Atherosclerotic
Novartis Pharmaceuticals334 enrolled20 locationsNCT06372925
Recruiting
Phase 4
6-month Clinical Investigation Assessing the Efficacy of an Antimicrobial Mouthrinse in Reducing Established Plaque and Improving Gum Health
GingivitisDental Plaque Accumulation
Colgate Palmolive90 enrolled1 locationNCT07414173
Recruiting
Phase 4
Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
Coronary Arterial Disease (CAD)Vulnerable Coronary PlaquesThin-cap fIbroatheroma+1 more
Beijing Anzhen Hospital2,190 enrolled1 locationNCT06855537
Recruiting
Phase 4
Bimekizumab in Plaque Psoriasis
Plaque Psoriasis
Icahn School of Medicine at Mount Sinai60 enrolled2 locationsNCT06336343
Recruiting
Phase 4
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
Coronary Artery DiseasePlaque, AtheroscleroticAtherosclerosis of Coronary Artery
Korea University Anam Hospital408 enrolled1 locationNCT06767345
Recruiting
Phase 4
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Atherosclerotic PlaqueIntracranial AtherosclerosisIntracranial Artery Stenosis
Peking Union Medical College Hospital300 enrolled19 locationsNCT06902740
Recruiting
Phase 4
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
Plaque Psoriasis
Singapore General Hospital40 enrolled1 locationNCT04537689
Active
Phase 3Phase 4
An Open-Label, Multicentre Study to Evaluate the Duration of Clinical Remission of Two Courses of Weekly Intramuscular administration of AMEVIVE (alefacept) by evaluating the time to retreatment with AMEVIVE or an alternative systemic therapy in patients with chronic plaque psoriasis in the context of standard dermatological practice
Chronic plaque psoriasis
Biogen Idec100 enrolled1 locationACTRN12605000295640